MDACC Study No:2004-0495 ( NCT No: NCT00209157)
Title:A Randomized, Comparative, Controlled Phase III Multicenter Study Of Hexvix Fluorescence Cystoscopy And White Light Cystoscopy In The Detection Of Papillary Bladder Cancer And The Early Recurrence Rate In Patients With Bladder Cancer
Principal Investigator:Barton Grossman
Treatment Agent:Hexvix
Study Status:Terminated
Study Description:The goal of this clinical research study is to see if the new drug Hexyl
5-aminolevulinate can help doctors to find bladder cancers more easily, which
may allow them to give a more appropriate treatment. Researchers will study
whether this way to find bladder cancer will lower the chances of the cancer
coming back 3, 6, and 9 months after the tumor has been removed. The safety of
this new drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase III
Treatment Agents:Hexvix
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:Patients will stay 23 hours or less at the time of cystoscopy. Some patients
may be discharged the same day.
Supported By:N/A
Return Visit:Patients will have a screening evaluation followed by cystoscopy/TURB and 3
follow up cystoscopic examinations three, six and nine months after the initial
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Barton Grossman
For Clinical Trial Enrollment:713-792-3250
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults